Organicell Regenerative Medicine Inc. Provides Update On Operations and Financial Reporting Status - Seite 2

In an effort to increase sales and mitigate anticipated near future restrictions expected to be imposed by the FDA with respect to the use and distribution of Section 351 designated biologics, the Company is seeking to develop sales and distribution channels outside of the United States.  In addition, the Company is focusing its efforts on developing other leading edge product offerings that would not fall within the FDA regulations for requiring a BLA license for U.S. manufacture and sale.

As a result of the Company’s expected future increase in processing requirements and to enable it to perform certain advanced research and development activities, the Company is currently in negotiations to relocate its laboratory facility during the second calendar quarter of 2020 to a larger “ISO 7” classified research and development and processing facility.

The Company has also been actively developing and expanding its sales, marketing and distribution network which it believes that based on the quality of the Company’s existing products, the Company’s commitment to regulatory compliance and superior research and development resources, the Company believes that it will be able to achieve desired growth during 2020.

The Company expects to provide periodic updates on operational and financial reporting developments as warranted.

For more information regarding the Company please visit our website at www.organicell.com.

About Organicell Regenerative Medicine, Inc.

Organicell is a leading, fully integrated Company focused in the field of regenerative medicine. Our world class research, technology, manufacturing and clinical development team is focused on creating new biologic medicines to revolutionize the field of regenerative medicine. We believe that our ground-breaking research in the field of nanotechnology, specifically exosome enrichments and other micro vesicles, is the next frontier of stem cell-based therapeutics. Organicell is committed to creating life changing and lifesaving therapies for patients. 

Our mission is to transform regenerative medicine by continuing to combine exosome technology with other synergistic therapies and become the healthcare technology incubator for biologic medicine.

CAUTIONARY COMMENT REGARDING FORWARD-LOOKING STATEMENTS 

The foregoing contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We intend for these forward-looking statements to be covered by the safe harbor provisions of the federal securities laws relating to forward-looking statements. This release contains forward-looking statements that reflect Organicell Regenerative Medicine Inc., and its subsidiaries, plans and expectations, financial situation, the ability to retain key personnel, product acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, ability to expand sales and channels, and legislation or regulations affecting our operations and the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties. You are cautioned not to rely on these forward-looking statements.  In this press release and related comments by Company management, words like "expect," "anticipate," "estimate," "intend", “believes” and similar expressions are used to identify forward-looking statements, representing management's current judgment and expectations about possible future events.